$1.50
-0.02 (-1.32%)
Open$1.51
Previous Close$1.52
Day High$1.57
Day Low$1.46
52W High$3.35
52W Low$1.42
Volume—
Avg Volume75.0K
Market Cap80.14M
P/E Ratio—
EPS$-0.11
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,826.0% upside
Current
$1.50
$1.50
Target
$28.89
$28.89
$16.92
$28.89 avg
$30.86
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 9.01M | 9.02M | 8.76M |
| Net Income | -596,230 | -528,269 | -565,775 |
| Profit Margin | -6.6% | -5.9% | -6.5% |
| EBITDA | -746,119 | -716,524 | -642,558 |
| Free Cash Flow | -600,890 | -503,274 | -433,552 |
| Rev Growth | +12.0% | +12.6% | +22.9% |
| Debt/Equity | 0.77 | 0.69 | 0.70 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |